Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

References

• LeitchHABucksteinBShamyAStorringJMThe immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guidelineCrit Rev Oncol Hematol201385216219222901762
   PubMed Web of Science ®Google Scholar
• MitchellMGoreSDZeidanAMIron chelation therapy in myelodysplastic syndromes: where do we stand?Expert Rev Hematol20136439741023991926
   PubMed Web of Science ®Google Scholar
• HuangTCKoBSTangJLComparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studiesLeukemia200822354455018094713
   PubMed Web of Science ®Google Scholar
• MalcovatiLHellström-LindbergEBowenDDiagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetBlood2013122172943296423980065
   PubMed Web of Science ®Google Scholar
• RådlundAThiedeTHansenSCarlssonMEngquistLIncidence of myelodysplastic syndromes in a Swedish populationEur J Haematol19955431531567720834
   PubMed Web of Science ®Google Scholar
• AulCGiagounidisAGermingUEpidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statisticsInt J Hematol200173440541011503953
   PubMed Web of Science ®Google Scholar
• GermingUStruppCKündgenANo increase in age-specific incidence of myelodysplastic syndromesHaematologica200489890591015339672
   PubMed Web of Science ®Google Scholar
• RollisonDEHowladerNSmithMTEpidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using datat from the NAACCR and SEER programsBlood20081121455218443215
   PubMed Web of Science ®Google Scholar
• NeukirchenJSchoonenWMStruppCIncidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registryLeuk Res201135121591159621708407
   PubMed Web of Science ®Google Scholar
• ZeidanAMFaltasBDouglas SmithBGoreSMyelodysplastic syndromes: what do hospitalists need to know?J Hosp Med20138635135723666619
   PubMed Web of Science ®Google Scholar
• ZeidanAMSmithBDKomrokjiRSGoreSDPrognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS)Am J Med20131264e2523507216
   PubMed Web of Science ®Google Scholar
• FaltasBZeidanAMGergisUMyelodysplastic syndromes: toward a risk-adapted treatment approachExpert Rev Hematol20136561162424094045
   PubMed Web of Science ®Google Scholar
• ZeidanAMKomrokjiRSThere’s risk, and then there’s RISK: The latest clinical prognostic risk stratification models in myelodysplastic syndromesCurr Hematol Malig Rep20138435136023979829
   PubMed Web of Science ®Google Scholar
• BennettJMCatovskyDDanielMTProposals for the classification of the myelodysplastic syndromesBr J Haematol19825121891996952920
   PubMed Web of Science ®Google Scholar
• VardimanJWThieleJArberDAThe 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood2009114593795119357394
   PubMed Web of Science ®Google Scholar
• GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood1997896207920889058730
   PubMed Web of Science ®Google Scholar
• MalcovatiLGermingUKuendgenATime-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesJ Clin Oncol200725233503351017687155
   PubMed Web of Science ®Google Scholar
• GreenbergPLTuechlerHSchanzJRevised international prognostic scoring system for myelodysplastic syndromesBlood2012120122454246522740453
   PubMed Web of Science ®Google Scholar
• BennettJMCatovskyDDanielMTProposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative groupBr J Haematol1976334451458188440
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSRavandiFProposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer200811361351136118618511
   PubMed Web of Science ®Google Scholar
• EisenmannKMDykemaKJMathesonSF5q-myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamicsOncogene200928393429344119597464
   PubMed Web of Science ®Google Scholar
• VoutsadakisIACairoliAA crtitical review of the molecular pathophysiology of lenalidomide sensitivity in 5q-myelodysplastic syndromesLeuk Lymphoma201253577978821955212
   PubMed Web of Science ®Google Scholar
• ZeidanAMGoreSDKomrokjiRSHigher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?Expert Rev Hematol20136325125423782079
   PubMed Web of Science ®Google Scholar
• FaltasBZeidanAGergisUMyelodysplastic syndromes: toward a risk-adapted treatment approachExpert Rev Hematol20136561162424094045
   PubMed Web of Science ®Google Scholar
• BoultwoodJLewisSWainscoatJSThe 5q-syndromeBlood19948410325332607949083
   PubMed Web of Science ®Google Scholar
• BoultwoodJPellagattiAMcKenzieANJWainscoatJSAdvances in the 5q-syndromeBlood2010116265803581120733155
   PubMed Web of Science ®Google Scholar
• van LeeuwenBHMartinsonMEWebbGCYoungIGMolecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5Blood1989735114211482564789
   PubMed Web of Science ®Google Scholar
• RobertsWMLookATRousselMFSherrCJTandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genesCell19885546556612846185
   PubMed Web of Science ®Google Scholar
• Van den BergheHCassimanJJDavidGFrynsJPMichauxJLSokalGDistinct haematological disorder with deletion of long arm of no 5 chromosomeNature197425154744374384421285
   PubMed Web of Science ®Google Scholar
• EbertBLDeletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancerLeukemia20092371252125619322210
   PubMed Web of Science ®Google Scholar
• KomrokjiRSPadronEEbertBLListAFDeletion 5q MDS: molecular and therapeutic implicationsBest Pract Res Clin Haematol201326436537524507813
   PubMed Web of Science ®Google Scholar
• GiagounidisAMuftiGJFenauxPGermingUListAMacBethKJLenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesAnn Hematol201493111124018623
   PubMed Web of Science ®Google Scholar
• EbertBLPretzJBoscoJIdentification of RPS14 as a 5q-syndrome gene by RNA interference screenNature2008451717633533918202658
   PubMed Web of Science ®Google Scholar
• NarlaAHurstSNEbertBLRibosome defects in disorders of erythropoiesisInt J Hematol201193214414921279816
   PubMed Web of Science ®Google Scholar
• ShiDGuWDual roles of MDM2 in the regulation of p53: ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activityGenes Cancer201233–424024823150757
   PubMedGoogle Scholar
• StarczynowskiDTKuchenbauerFArgiropoulosBIdentification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotypeNat Med2010161495819898489
   PubMed Web of Science ®Google Scholar
• StarczynowskiDTKarsanADeregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5qCell Cycle20109585585620160505
   PubMed Web of Science ®Google Scholar
• LehmannSO’KellyJRaynaudSFunkSESageEHKoefflerHPCommon deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null miceLeukemia20072191931193617625608
   PubMed Web of Science ®Google Scholar
• AdèsLFenauxPImmunomodulating drugs in myelodysplastic syndromesHematology Am Soc Hematol Educ Program2011201155656022160089
   PubMed Web of Science ®Google Scholar
• KelaidiCParkSBrechignacSTreatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomideLeuk Res20083271049105318191202
   PubMed Web of Science ®Google Scholar
• RazaAMeyerPDuttDThalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromesBlood200198495896511493439
   PubMed Web of Science ®Google Scholar
• Moreno-AspitiaAColon-OteroGHoeringAThalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group Phase II trialCancer2006107476777216826578
   PubMed Web of Science ®Google Scholar
• StruppCHildebrandtBGermingUHaasRGattermannNCytogenetic response to thalidomide treatment in three patients with myelodysplastic syndromeLeukemia20031761200120212764395
   PubMed Web of Science ®Google Scholar
• WeiSChenXMcGrawKLenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionOncogene20133291110112022525275
   PubMed Web of Science ®Google Scholar
• ListADewaldGBennettJLenalidomide in the myelodysplastic syndrome with chromosome 5q deletionN Engl J Med2006355141456146517021321
   PubMed Web of Science ®Google Scholar
• NarlaADuttSMcAuleyJRDexamethasone and lenalidomide have distinct functional effects on erythropoiesisBlood201111882296230421527522
   PubMed Web of Science ®Google Scholar
• ListAFEstesMWilliamsALenalidomide (CC-5013; Revlimid) promotes erythropoiesis in myelodysplastic syndromes (MDS) by CD45 protein tyrosine phosphatase (PTP) inhibitionASH Annual Meeting Abstracts20061081360
   Google Scholar
• KomrokjiRSListAFRole of lenalidomide in the treatment of myelodysplastic syndromesSemin Oncol201138564865721943671
   PubMed Web of Science ®Google Scholar
• CorralLGHaslettPAMullerGWDifferential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNT-alphaJ Immunol1999163138038610384139
   PubMed Web of Science ®Google Scholar
• SymeonidisAKourakliAKatevasPImmune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosisEur J Haematol19914742772811954986
   PubMed Web of Science ®Google Scholar
• KotlaVGoelSNischalSMechanism of action of lenalidomide in hematological malignanciesJ Hematol Oncol200923619674465
   PubMed Web of Science ®Google Scholar
• Epling-BurnettePKHanYMaillouxAWNovel predictor of lenalidomide response in non-del5q MDS reveals linkage to molecular mechanism: first characterization of T-cell function in cereblon homozygous deficient mice55th ASH Annual Meeting and Exposition2013 Available from: https://ash.confex.com/ash/2013/webprogram/Paper65378.htmlAccessed August 28, 2014
   Google Scholar
• GuptaDTreonSPShimaYAdherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applicationsLeukemia200115121950196111753617
   PubMed Web of Science ®Google Scholar
• TeoSKProperties of thalidomide and its analogues: implications for anticancer therapyAAPS J200571E14E1916146335
   PubMed Web of Science ®Google Scholar
• GiagounidisAAGermingUHaaseSClinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31Leukemia200418111311914586479
   PubMed Web of Science ®Google Scholar
• SchermanEMalakSPerotCGorinNCRubioMTIsnardFInterest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotypeLeukemia201226482282421997572
   PubMed Web of Science ®Google Scholar
• ListAKurtinSRoeDJEfficacy of lenalidomide in myelodysplastic syndromesN Engl J Med2005352654955715703420
   PubMed Web of Science ®Google Scholar
• FenauxPGiagounidisASelleslagDA randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5qBlood2011118143765377621753188
   PubMed Web of Science ®Google Scholar
• ListAFBennettJMSekeresMAExtended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDSLeukemia20142851033104024150217
   PubMed Web of Science ®Google Scholar
• OlivaENLatagliataRMorabitoFLenalidomide for the treatment of low- and int-1-risk MDS with del(5q): efficacy and quality of life studyBlood200911421080
   Google Scholar
• GöhringGGiagounidisABüscheGPatients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progressionAnn Hematol201089436537419855965
   PubMed Web of Science ®Google Scholar
• AdèsLLe BrasFSebertMTreatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des MyelodysplasiesHaematologica201297221321821993675
   PubMed Web of Science ®Google Scholar
• KuendgenALausekerMListAFLenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysisLeukemia20132751072107923257782
   PubMed Web of Science ®Google Scholar
• AdèsLBoehrerSPrebetTEfficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyBlood2009113173947395218987358
   PubMed Web of Science ®Google Scholar
• MöllgårdLSaftLTreppendahlMBClinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalitiesHaematologica201196796397121719884
   PubMed Web of Science ®Google Scholar
• RazaAReevesJAFeldmanEJPhase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qBlood20081111869317893227
   PubMed Web of Science ®Google Scholar
• EbertBLGaliliNTamayoPAn erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndromePLoS One200852e35
   Google Scholar
• TomaAA randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPOJ Clin Oncol201331Suppl 15 Abstr 7002
   Web of Science ®Google Scholar
• JäderstenMSaftLSmithATP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progressionJ Clin Oncol201129151971197921519010
   PubMed Web of Science ®Google Scholar
• GiagounidisAALenalidomide for del(5q) and non-del(5q) myelodysplastic syndromesSemin Hematol201249431232223079061
   PubMed Web of Science ®Google Scholar
• MalloMDel ReyMIbáñezMResponse to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutationsBr J Haematol20131621748623614682
   PubMed Web of Science ®Google Scholar
• Fernandez-MercadoMBurnsAPellagattiATargeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromesHaematologica201398121856186423831921
   PubMed Web of Science ®Google Scholar
• SugimotoYSekeresMAMakishimaHCytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomideJ Hematol Oncol20125422390313
   PubMed Web of Science ®Google Scholar
• WuLLiXXuFZhangZChangCHeQLow RPS14 expression in MDS without 5q – aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q-patientsEur J Haematol201390648649323506134
   PubMed Web of Science ®Google Scholar
• SardnalVRouquetteAKaltenbachSA G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)Leukemia20132771610161323434730
   PubMed Web of Science ®Google Scholar
• CaceresGMcGrawKYipBHTP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patientsProc Natl Acad Sci U S A201311040161271613224043769
   PubMed Web of Science ®Google Scholar
• TehranchiRWollPSAndersonKPersistent malignant stem cells in del(5q) myelodysplasia in remissionN Engl J Med2010363111025103720825315
   PubMed Web of Science ®Google Scholar
• KomrokjiRSLancetJESwernASCombined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndromeBlood2012120173419342422936658
   PubMed Web of Science ®Google Scholar
• WangESLyonsRMLarsonRAA randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideJ Hematol Oncol201257123190430
   PubMed Web of Science ®Google Scholar
• WörmannBClinical indications for thrombopoietin and thrombopoietin-receptor agonistsTransfus Med Hemother201340531932524273485
   PubMed Web of Science ®Google Scholar
• SekeresMATiuRVKomrokjiRPhase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesBlood2012120254945495122915641
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUBraulkeFKündgenASequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I studyLeukemia20132761403140723354011
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGDaverNGBorthakurGPhase I study of the combination of 5-azacitidine sequentially with high-dose lenalidomide in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)Blood20111181122
   Web of Science ®Google Scholar
• PlatzbeckerUGermingUCombination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia – a wise liaison?Leukemia20132791813181923644421
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
   PubMed Web of Science ®Google Scholar
• ZeidanAMLinharesYGoreSDCurrent therapy of myelodysplastic syndromesBlood Rev201327524325923954262
   PubMed Web of Science ®Google Scholar
• RazaAGaliliNMulfordDPhase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)J Hematol Oncol201251822546242
   PubMed Web of Science ®Google Scholar
• ZeidanAMGoreSDMcNallyDLLenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromesCancer2013119213870387823922173
   PubMed Web of Science ®Google Scholar
• GossTFSzendeASchaeferCCost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United StatesCancer Control200613Suppl172517242663
   PubMedGoogle Scholar
• DuongVHKomrokjiRSListAFEfficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletionTher Adv Hematol20123210511623556117
   PubMedGoogle Scholar
• Le BrasFSebertMKelaidiCTreatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion – the GFM experienceLeuk Res201135111444144821715006
   PubMed Web of Science ®Google Scholar
• ZeidanAMKharfan-DabajaMAKomrokjiRSBeyond hypomethylating agents failure in patients with myelodysplastic syndromesCurr Opin Hematol201421212313024335709
   PubMed Web of Science ®Google Scholar
• BarlowJLDrynanLFHewettDRA p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndromeNat Med2010161596619966810
   PubMed Web of Science ®Google Scholar
• WeiSChenXRochaKA critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomideProc Natl Acad Sci U S A200910631129741297919470455
   PubMed Web of Science ®Google Scholar
• DeWardADLealiKWestRAPrendergastGCAlbertsASLoss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout micePLoS One200949e710219768111
   PubMed Web of Science ®Google Scholar